GSK Stock Analysis: Buy, Sell, or Hold?
GSK - GSK plc American Depositary Shares (Each representing two Ordinary Shares)
$54.32
0.48 (0.89%)
▲
5d:
+4.48%
30d:
-8.13%
90d:
+10.68%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: Apr 29, 2026
29d
Get Alerted When GSK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GSK shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: GSK shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$74.15
Based on 5.8% avg growth
INTRINSIC VALUE TODAY
$46.04
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GSK is currently trading at $54.32, which is considered fair relative to its 30-day fair value range of $52.94 to $58.22. The stock's valuation (Forward PE: 10.5) is in line with its historical norms (10.9). Remarkably, the market is currently pricing in an annual earnings decline of 1.2% over the next few years. This pessimistic expectation contrasts with the company's recent 54.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GSK is in a strong uptrend. The price is approaching resistance at $54.98. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GSK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GSK is in a strong uptrend. The price is approaching resistance at $54.98. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GSK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$52.94 -
$58.22
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
78.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($57.48)
Fair Price Analysis
30-Day Fair Range
$52.94 -
$58.22
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$51.55
Resistance Level
$54.98
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.49
Wall Street Target
$57.48
(+6.8%)
Revenue Growth (YoY)
6.2%
Earnings Growth (YoY)
54.7%
Profit Margin
17.5%
Valuation Discount vs History
-1.2% cheaper
PE vs Historical
10.5 vs 10.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.2%
(market-implied from PE analysis)
1-Year Target
$53.19
(-1%)
2-Year Target
$52.56
(-2%)
3-Year Target
$51.92
(-4%)
3-Yr Target (if PE normalizes)
(PE: 10→11)
$53.96
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 7.6%)
$143.21
(+166%)
Base:
(SPY PE: 10.5, Growth: 7.6%)
$67.05
(+25%)
Bear:
(PE: 8.9, Growth: 7.6%)
$56.99
(+6%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 14.09 | Current EPS (TTM): $3.68
Bull Case
$79.55
(+53%)
Analyst growth 39.5%, PE expands to 15.5
Base Case
$72.31
(+39%)
Market implied 39.5%, PE stable at 14.1
Bear Case
$35.25
(-32%)
Severe decline -20.0%, PE contracts to 12.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.5 to 10.9
Stabilization Target:
$55.95
(+3.9%)
PE Expansion Potential:
+3.9%
Share & Embed Analysis
Last updated: March 30, 2026 1:57 PM ET
Data refreshes hourly during market hours. Next update: 2:57 PM
Data refreshes hourly during market hours. Next update: 2:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GSK showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Plc Gsk
BUY
1470000 shares
2025-12-11
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1209 | 54 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 56 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$206 | 64 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$351 | 58 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$249 | 56 HOLD |
